Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension

Daniel E. Hilleman, Syed M. Mohiuddin, B. D. Lucas, J. A. Stading, A. M. Stoysich, K. Ryschon

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

In addition to efficacy and safety, the cost of therapy has become an increasingly important factor to consider when selecting drugs to treat patients with mild-to-moderate hypertension. However, acquisition prices alone do not determine the total cost of therapy. To better assess total costs, we conducted a systematic, retrospective, cost-minimization analysis of drugs used to treat 673 patients with newly diagnosed, mild-to-moderate (>95 to 2-agonists, alpha1-adrenergic blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors. Costs, adjusted to 1992 price levels, were analyzed for 32 individual agents for each of the following five cost variables: initial drug acquisition, supplemental drug acquisition, laboratory monitoring, clinic visits, and treatment of side effects. Mean total costs per patient for all five variables by drug class were $895 for beta-blockers, $1043 for diuretics, $1165 for centrally acting alpha2-agonists, $1243 for ACE inhibitors, $1288 for alpha1-blockers, and $1425 for calcium channel blockers. However, costs within each class varied considerably. Acquisition cost was often a poor predictor of the total cost of treatment. Therefore, acquisition cost must be considered in conjunction with a number of outcome variables to assess the true cost of antihypertensive therapy.

Original languageEnglish
Pages (from-to)88-102
Number of pages15
JournalClinical Therapeutics
Volume16
Issue number1
StatePublished - 1994

Fingerprint

Antihypertensive Agents
Costs and Cost Analysis
Therapeutics
Pharmaceutical Preparations
Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Essential Hypertension
Adrenergic Antagonists
Ambulatory Care
Diuretics
Health Care Costs
Hypertension
Safety

All Science Journal Classification (ASJC) codes

  • Pharmacology

Cite this

Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension. / Hilleman, Daniel E.; Mohiuddin, Syed M.; Lucas, B. D.; Stading, J. A.; Stoysich, A. M.; Ryschon, K.

In: Clinical Therapeutics, Vol. 16, No. 1, 1994, p. 88-102.

Research output: Contribution to journalArticle

@article{ca22751aea7a46deb68b443411c93312,
title = "Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension",
abstract = "In addition to efficacy and safety, the cost of therapy has become an increasingly important factor to consider when selecting drugs to treat patients with mild-to-moderate hypertension. However, acquisition prices alone do not determine the total cost of therapy. To better assess total costs, we conducted a systematic, retrospective, cost-minimization analysis of drugs used to treat 673 patients with newly diagnosed, mild-to-moderate (>95 to 2-agonists, alpha1-adrenergic blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors. Costs, adjusted to 1992 price levels, were analyzed for 32 individual agents for each of the following five cost variables: initial drug acquisition, supplemental drug acquisition, laboratory monitoring, clinic visits, and treatment of side effects. Mean total costs per patient for all five variables by drug class were $895 for beta-blockers, $1043 for diuretics, $1165 for centrally acting alpha2-agonists, $1243 for ACE inhibitors, $1288 for alpha1-blockers, and $1425 for calcium channel blockers. However, costs within each class varied considerably. Acquisition cost was often a poor predictor of the total cost of treatment. Therefore, acquisition cost must be considered in conjunction with a number of outcome variables to assess the true cost of antihypertensive therapy.",
author = "Hilleman, {Daniel E.} and Mohiuddin, {Syed M.} and Lucas, {B. D.} and Stading, {J. A.} and Stoysich, {A. M.} and K. Ryschon",
year = "1994",
language = "English",
volume = "16",
pages = "88--102",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "1",

}

TY - JOUR

T1 - Cost-minimization analysis of initial antihypertensive therapy in patients with mild-to-moderate essential diastolic hypertension

AU - Hilleman, Daniel E.

AU - Mohiuddin, Syed M.

AU - Lucas, B. D.

AU - Stading, J. A.

AU - Stoysich, A. M.

AU - Ryschon, K.

PY - 1994

Y1 - 1994

N2 - In addition to efficacy and safety, the cost of therapy has become an increasingly important factor to consider when selecting drugs to treat patients with mild-to-moderate hypertension. However, acquisition prices alone do not determine the total cost of therapy. To better assess total costs, we conducted a systematic, retrospective, cost-minimization analysis of drugs used to treat 673 patients with newly diagnosed, mild-to-moderate (>95 to 2-agonists, alpha1-adrenergic blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors. Costs, adjusted to 1992 price levels, were analyzed for 32 individual agents for each of the following five cost variables: initial drug acquisition, supplemental drug acquisition, laboratory monitoring, clinic visits, and treatment of side effects. Mean total costs per patient for all five variables by drug class were $895 for beta-blockers, $1043 for diuretics, $1165 for centrally acting alpha2-agonists, $1243 for ACE inhibitors, $1288 for alpha1-blockers, and $1425 for calcium channel blockers. However, costs within each class varied considerably. Acquisition cost was often a poor predictor of the total cost of treatment. Therefore, acquisition cost must be considered in conjunction with a number of outcome variables to assess the true cost of antihypertensive therapy.

AB - In addition to efficacy and safety, the cost of therapy has become an increasingly important factor to consider when selecting drugs to treat patients with mild-to-moderate hypertension. However, acquisition prices alone do not determine the total cost of therapy. To better assess total costs, we conducted a systematic, retrospective, cost-minimization analysis of drugs used to treat 673 patients with newly diagnosed, mild-to-moderate (>95 to 2-agonists, alpha1-adrenergic blockers, calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors. Costs, adjusted to 1992 price levels, were analyzed for 32 individual agents for each of the following five cost variables: initial drug acquisition, supplemental drug acquisition, laboratory monitoring, clinic visits, and treatment of side effects. Mean total costs per patient for all five variables by drug class were $895 for beta-blockers, $1043 for diuretics, $1165 for centrally acting alpha2-agonists, $1243 for ACE inhibitors, $1288 for alpha1-blockers, and $1425 for calcium channel blockers. However, costs within each class varied considerably. Acquisition cost was often a poor predictor of the total cost of treatment. Therefore, acquisition cost must be considered in conjunction with a number of outcome variables to assess the true cost of antihypertensive therapy.

UR - http://www.scopus.com/inward/record.url?scp=0028242448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028242448&partnerID=8YFLogxK

M3 - Article

C2 - 7911403

AN - SCOPUS:0028242448

VL - 16

SP - 88

EP - 102

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 1

ER -